ID   HTh104
AC   CVCL_A427
AS   CVCL_6477
SY   HTh 104; HTh-104; Uhth-104; U-Hth104; U-hth104
DR   cancercelllines; CVCL_A427
DR   Cosmic; 1068620
DR   Cosmic; 1239962
DR   Cosmic; 2054083
DR   Cosmic; 2050370
DR   Wikidata; Q54896653
RX   PubMed=17465858;
RX   PubMed=18713817;
RX   PubMed=21868764;
RX   PubMed=23833040;
RX   PubMed=30737244;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:3373; EP300; Simple; p.Pro16fs (c.46delC); Zygosity=Unspecified (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:9801; RAC1; Simple; p.Pro29Ala (c.85C>G); Zygosity=Unspecified (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=17465858; PubMed=18713817; PubMed=21868764; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 8,9,12 (PubMed=21868764)
ST   D16S539: 8,12 (PubMed=30737244)
ST   D18S51: 14,18 (PubMed=17465858)
ST   D18S51: 14,19 (PubMed=18713817; PubMed=30737244)
ST   D21S11: 27,31.2
ST   D3S1358: 14
ST   D5S818: 12
ST   D7S820: 10
ST   D8S1179: 12,13
ST   FGA: 23
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 14,16
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   72Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 21
//
RX   PubMed=17465858; DOI=10.1089/thy.2006.0246;
RA   Lee J.-J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E.,
RA   Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.;
RT   "Molecular cytogenetic profiles of novel and established human
RT   anaplastic thyroid carcinoma models.";
RL   Thyroid 17:289-301(2007).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//